In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crucell Vaccine Institute

Division of Johnson & Johnson
www.crucell.com

Latest From Crucell Vaccine Institute

Keeping Track: Ofev Snags SSc-ILD Indication, Accelerated Approval Reviews For Veverimer And Voxelotor, J&J Gets Its First Vaccine BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Janssen R&D Unveils Three New Research Platforms

With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.

BioPharmaceutical Clinical Trials

Recent Tech Transfer Deals, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register